Swedish healthcare group Sobi has appointed Torbjorn Hallberg as its new general counsel and establishes a new leadership structure.
Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.
He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as Ferring and Nycomed.
Meanwhile, Sobi has also established a new leadership structure, consisting of chief executive officer Guido Oelkers, chief financial officer Mats-Olof Wallin, general counsel and head of legal affairs Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.
Also sitting on the new team are Sobi’s head of specialty care Norbert Oppitz, head of medical and scientific affairs Armin Reininger, head of haemophilia Philip Wood and head of research and development and chief medical officer Milan Zdravkovic.
Source: PMLive
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.
